Do XXXX predict outcome in @entity1 with @entity3271 ?

@entity1 @entity410 @entity302 @entity204 @entity3271
BACKGROUND: Many @entity1 with an @entity3271 ( @entity3271 ) experience @entity410 , some of which become refractory to @entity302 ( @entity302 ). This study aims (1) to quantify the rate of @entity410 and medically @entity302 in @entity1 with ODs; and (2) to determine if there is any association between short-term and long-term survival, and the presence and drug-responsiveness of @entity410 . METHODS: A retrospective review was conducted of the medical records of @entity1 who had been pathologically identified as having an @entity3271 at the London Health Sciences Centre or the London Regional Cancer Program in London, Ontario from January 1996 to July 2008. Deaths were ascertained by reviewing all hospital records. Survival analysis was performed. RESULTS: One-hundred sixty-six @entity1 met inclusion criteria. @entity302 were the presenting feature or occurred as part of the initial manifestation of the @entity3271 in 75.3% of @entity1 , with 90.4% (n=150) experiencing at least one @entity410 and 76.5% developing @entity302 over the course of observation. Of the 150 @entity1 with @entity410 , 23 experienced a single @entity410 (13.9% of the 166), whereas 127 @entity1 experienced multiple @entity410 (76.5%). In those with multiple @entity410 , the @entity302 was refractory to drug treatment slightly more than half the time (54.3%). Survival analysis demonstrated consistently superior survival among those with a single @entity410 . Those without @entity410 had the worst survival rates over the first few years post-diagnosis; but then no further @entity204 occurred. Survival among those with refractory @entity410 tended to be better than among those whose @entity410 were drug responsive, over the first 10 years post-diagnosis. CONCLUSIONS: @entity410 are common and may influence survival in @entity1 with oligodendogliomas. Those who experience just one @entity410 appear to do best.
